Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States
In this real-world analysis, CAR T was associated with longer TTNT, longer TFI, and lower downstream FL-related costs compared with non-CAR T therapy, with interpretation informed by differences in follow-up time and treatment context.
Authors
- Karl M. Kilgore (ORCID: https://orcid.org/0000-0003-1103-2107)
- Christie Teigland (ORCID: https://orcid.org/0000-0003-4887-8077)
- Andrew Ip (ORCID: https://orcid.org/0000-0003-0456-5618)
- Iman Mohammadi (ORCID: https://orcid.org/0000-0003-2775-1149)
- Markqayne Ray (ORCID: https://orcid.org/0000-0001-8691-3756)
- Philip K Chan
Institutions
- Hackensack University Medical Center (US)
- Hackensack Meridian Health (US)
- Myovant Sciences (United States) (US)
- Gilead Sciences (France) (FR)
Publication Details
- Journal
- Future Oncology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1080/14796694.2026.2633443
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00